Windward Capital Management Co. CA Trims Stake in Thermo Fisher Scientific Inc. $TMO

Windward Capital Management Co. CA decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 32,925 shares of the medical research company’s stock after selling 1,141 shares during the quarter. Thermo Fisher Scientific accounts for 1.5% of Windward Capital Management Co. CA’s portfolio, making the stock its 20th largest position. Windward Capital Management Co. CA’s holdings in Thermo Fisher Scientific were worth $19,078,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. JPL Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the third quarter worth about $28,000. Beacon Financial Strategies CORP acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Olistico Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Cloud Capital Management LLC acquired a new position in Thermo Fisher Scientific in the third quarter worth about $31,000. Finally, KERR FINANCIAL PLANNING Corp bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $38,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on TMO shares. Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Citigroup lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a report on Friday, January 30th. Barclays dropped their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday. Finally, UBS Group reissued a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $625.55.

Thermo Fisher Scientific Stock Down 9.2%

Thermo Fisher Scientific stock opened at $466.93 on Friday. The company’s 50-day moving average price is $499.83 and its two-hundred day moving average price is $549.98. The stock has a market cap of $173.52 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 2.66 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the firm posted $5.15 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 24.68 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a $0.47 dividend. The ex-dividend date of this dividend was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.60%.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat on both revenue and EPS (revenue $11.01B, EPS $5.44) and management raised full‑year outlook — this confirms cash flow and margin resilience. Thermo Fisher posts quarterly results beat
• Neutral Sentiment: The company issued FY2026 EPS guidance of $24.64–$25.12 (close to, but slightly below consensus midpoint) and revenue guidance roughly in line with estimates — raises uncertainty about near‑term growth trajectory despite the raised outlook. Thermo Fisher Raises 2026 Outlook
• Neutral Sentiment: Management flagged a “modest inflation” risk amid Middle East tensions, which could modestly pressure costs/pricing but is not currently a major driver. Thermo Fisher Flags ‘Modest Inflation’ Risk
• Positive Sentiment: Analysts and bulls emphasize long‑term growth drivers (biopharma services, lab products, AI/digital lab tailwinds and reshoring) and some firms reiterated Buy ratings on the pullback. Thermo Fisher Earnings Call Signals Confident Outlook
• Negative Sentiment: Investors punished the stock after the quarter because management highlighted weak underlying organic growth and mixed segment performance; the result was a sharp intraday drop as traders focused on momentum risks. Why Thermo Fisher (TMO) Stock Is Nosediving
• Negative Sentiment: Two brokers cut price targets this morning (Stifel: $700 → $600, Baird: $653 → $639), signaling reduced near‑term upside and amplifying selling pressure. Benzinga The Fly
• Negative Sentiment: Broader market and sector weakness (tech-led selloff, US‑Iran tensions) intensified the stock’s decline and pressured peers, suggesting a risk-off backdrop beyond company specifics. Stocks Settle Lower on US-Iran Stalemate

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.